Healthcare -
Biotechnology - NASDAQ - US
$ 0.53
6 %
$ 13.3 M
Market Cap
-0.45
P/E
1. INTRINSIC VALUE
Balance Sheet
Sensei Biotherapeutics, Inc.
| Current Assets | 67.2 M |
| Cash & Short-Term Investments | 65.8 M |
| Receivables | 0 |
| Other Current Assets | 1.49 M |
| Non-Current Assets | 7.12 M |
| Long-Term Investments | 0 |
| PP&E | 7.04 M |
| Other Non-Current Assets | 86 K |
| Current Liabilities | 5.64 M |
| Accounts Payable | 1.69 M |
| Short-Term Debt | 2.44 M |
| Other Current Liabilities | 1.51 M |
| Non-Current Liabilities | 3.84 M |
| Long-Term Debt | 3.77 M |
| Other Non-Current Liabilities | 67 K |
EFFICIENCY
Earnings Waterfall
Sensei Biotherapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 571 K |
| Gross Profit | -571 K |
| Operating Expenses | 37.1 M |
| Operating Income | -37.1 M |
| Other Expenses | -2.96 M |
| Net Income | -34.1 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Sensei Biotherapeutics, Inc.
| Net Income | -34.1 M |
| Depreciation & Amortization | 1.35 M |
| Capital Expenditures | -180 K |
| Stock-Based Compensation | 4.45 M |
| Change in Working Capital | -4.33 M |
| Others | -1.4 M |
| Free Cash Flow | -32.2 M |
Wall Street Analysts Price Targets
Sensei Biotherapeutics, Inc.
Wall Street analysts predict an average 1-year price target for SNSE of $5 , with forecasts ranging from
a
low of
$5 to a high of $5 .
SNSE Lowest Price Target
Wall Street Target
5 USD
843.40%
SNSE Average Price Target
Wall Street Target
5 USD
843.40%
SNSE Highest Price Target
Wall Street Target
5 USD
843.40%
4. DIVIDEND
ANALYSIS
SNSE does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Sensei Biotherapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Sep 11, 2023
|
Bought
425 USD
|
Celebi John
President and CEO
|
+ 500
|
0.85 USD |
|
1 year ago
Jun 01, 2023
|
Sell 1.51 M
USD
|
Apeiron Investment Group Ltd.
10 percent owner
|
- 955738
|
1.58 USD |
|
1 year ago
Feb 23, 2023
|
Bought
1.76 K USD
|
Apeiron Investment Group Ltd.
10 percent owner
|
+ 1100
|
1.6023 USD |
|
1 year ago
Feb 23, 2023
|
Bought
1.78 K USD
|
Apeiron Investment Group Ltd.
10 percent owner
|
+ 1100
|
1.615 USD |
|
2 years ago
Mar 02, 2022
|
Bought
3.85 K USD
|
Peyer James
director, 10 percent owner:
|
+ 1203
|
3.2 USD |
|
2 years ago
Mar 02, 2022
|
Bought
3.85 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 1203
|
3.2 USD |
|
3 years ago
Mar 23, 2021
|
Bought
136 K USD
|
Peyer James
director, 10 percent owner:
|
+ 9500
|
14.34 USD |
|
3 years ago
Feb 18, 2021
|
Bought
14.9 K USD
|
Peyer James
director, 10 percent owner:
|
+ 752
|
19.75 USD |
|
3 years ago
Mar 23, 2021
|
Bought
136 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 9500
|
14.34 USD |
|
3 years ago
Feb 18, 2021
|
Bought
14.9 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 752
|
19.75 USD |
|
2 years ago
Mar 02, 2022
|
Bought
3.85 K USD
|
Cambrian BioPharma Inc
director:
|
+ 1203
|
3.2 USD |
|
2 years ago
Mar 02, 2022
|
Bought
3.85 K USD
|
Peyer James
director:
|
+ 1203
|
3.2 USD |
|
2 years ago
Mar 01, 2022
|
Bought
8.85 K USD
|
Peyer James
director, 10 percent owner:
|
+ 2458
|
3.6 USD |
|
2 years ago
Feb 28, 2022
|
Bought
151 USD
|
Peyer James
director, 10 percent owner:
|
+ 42
|
3.6 USD |
|
2 years ago
Mar 01, 2022
|
Bought
8.85 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 2458
|
3.6 USD |
|
2 years ago
Feb 28, 2022
|
Bought
151 USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 42
|
3.6 USD |
|
2 years ago
Feb 25, 2022
|
Bought
9.12 K USD
|
Peyer James
director, 10 percent owner:
|
+ 2500
|
3.65 USD |
|
2 years ago
Feb 25, 2022
|
Bought
9.12 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 2500
|
3.65 USD |
|
2 years ago
Feb 24, 2022
|
Bought
54.4 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 15000
|
3.63 USD |
|
2 years ago
Feb 23, 2022
|
Bought
9.5 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 2500
|
3.8 USD |
|
2 years ago
Feb 24, 2022
|
Bought
54.4 K USD
|
Peyer James
director, 10 percent owner:
|
+ 15000
|
3.63 USD |
|
2 years ago
Feb 23, 2022
|
Bought
9.5 K USD
|
Peyer James
director, 10 percent owner:
|
+ 2500
|
3.8 USD |
|
2 years ago
Feb 18, 2022
|
Bought
59.6 K USD
|
Peyer James
director, 10 percent owner:
|
+ 15000
|
3.97 USD |
|
2 years ago
Feb 17, 2022
|
Bought
20.6 K USD
|
Peyer James
director, 10 percent owner:
|
+ 4949
|
4.17 USD |
|
2 years ago
Feb 18, 2022
|
Bought
59.6 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 15000
|
3.97 USD |
|
2 years ago
Feb 17, 2022
|
Bought
20.6 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 4949
|
4.17 USD |
|
2 years ago
Feb 16, 2022
|
Bought
10.8 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 2551
|
4.25 USD |
|
2 years ago
Feb 14, 2022
|
Bought
41.8 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 10000
|
4.18 USD |
|
2 years ago
Feb 16, 2022
|
Bought
10.8 K USD
|
Peyer James
director, 10 percent owner:
|
+ 2551
|
4.25 USD |
|
2 years ago
Feb 14, 2022
|
Bought
41.8 K USD
|
Peyer James
director, 10 percent owner:
|
+ 10000
|
4.18 USD |
|
2 years ago
Feb 11, 2022
|
Bought
55 K USD
|
Peyer James
director, 10 percent owner:
|
+ 12500
|
4.4 USD |
|
2 years ago
Feb 10, 2022
|
Bought
22.9 K USD
|
Peyer James
director, 10 percent owner:
|
+ 5000
|
4.58 USD |
|
2 years ago
Feb 11, 2022
|
Bought
55 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 12500
|
4.4 USD |
|
2 years ago
Feb 10, 2022
|
Bought
22.9 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 5000
|
4.58 USD |
|
2 years ago
Feb 08, 2022
|
Bought
43.3 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 10000
|
4.33 USD |
|
2 years ago
Feb 04, 2022
|
Bought
11.1 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 2500
|
4.45 USD |
|
2 years ago
Feb 03, 2022
|
Bought
81.4 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 17500
|
4.65 USD |
|
2 years ago
Feb 08, 2022
|
Bought
43.3 K USD
|
Peyer James
director, 10 percent owner:
|
+ 10000
|
4.33 USD |
|
2 years ago
Feb 04, 2022
|
Bought
11.1 K USD
|
Peyer James
director, 10 percent owner:
|
+ 2500
|
4.45 USD |
|
2 years ago
Feb 03, 2022
|
Bought
81.4 K USD
|
Peyer James
director, 10 percent owner:
|
+ 17500
|
4.65 USD |
|
2 years ago
Jan 28, 2022
|
Bought
37.6 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 8900
|
4.22 USD |
|
2 years ago
Jan 27, 2022
|
Bought
26.3 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 6100
|
4.31 USD |
|
2 years ago
Jan 28, 2022
|
Bought
37.6 K USD
|
Peyer James
director, 10 percent owner:
|
+ 8900
|
4.22 USD |
|
2 years ago
Jan 27, 2022
|
Bought
26.3 K USD
|
Peyer James
director, 10 percent owner:
|
+ 6100
|
4.31 USD |
|
2 years ago
Jan 26, 2022
|
Bought
138 K USD
|
Peyer James
director, 10 percent owner:
|
+ 29900
|
4.62 USD |
|
2 years ago
Jan 25, 2022
|
Bought
97.7 K USD
|
Peyer James
director, 10 percent owner:
|
+ 20100
|
4.86 USD |
|
2 years ago
Jan 26, 2022
|
Bought
138 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 29900
|
4.62 USD |
|
2 years ago
Jan 25, 2022
|
Bought
97.7 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 20100
|
4.86 USD |
|
2 years ago
Jan 24, 2022
|
Bought
106 K USD
|
Peyer James
director, 10 percent owner:
|
+ 22707
|
4.69 USD |
|
2 years ago
Jan 21, 2022
|
Bought
122 K USD
|
Peyer James
director, 10 percent owner:
|
+ 24703
|
4.94 USD |
|
2 years ago
Jan 24, 2022
|
Bought
106 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 22707
|
4.69 USD |
|
2 years ago
Jan 21, 2022
|
Bought
122 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 24703
|
4.94 USD |
|
3 years ago
Jan 20, 2022
|
Bought
103 K USD
|
Peyer James
director, 10 percent owner:
|
+ 20000
|
5.17 USD |
|
3 years ago
Jan 19, 2022
|
Bought
50.9 K USD
|
Peyer James
director, 10 percent owner:
|
+ 10244
|
4.97 USD |
|
3 years ago
Jan 20, 2022
|
Bought
103 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 20000
|
5.17 USD |
|
3 years ago
Jan 19, 2022
|
Bought
50.9 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 10244
|
4.97 USD |
|
3 years ago
Jan 18, 2022
|
Bought
50.8 K USD
|
Peyer James
director, 10 percent owner:
|
+ 10000
|
5.08 USD |
|
3 years ago
Jan 18, 2022
|
Bought
50.8 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 10000
|
5.08 USD |
|
3 years ago
Jan 14, 2022
|
Bought
31 K USD
|
Peyer James
director, 10 percent owner:
|
+ 6219
|
4.99 USD |
|
3 years ago
Jan 13, 2022
|
Bought
102 K USD
|
Peyer James
director, 10 percent owner:
|
+ 19953
|
5.13 USD |
|
3 years ago
Jan 14, 2022
|
Bought
31 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 6219
|
4.99 USD |
|
3 years ago
Jan 13, 2022
|
Bought
102 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 19953
|
5.13 USD |
|
3 years ago
Jan 12, 2022
|
Bought
48 K USD
|
Peyer James
director, 10 percent owner:
|
+ 9202
|
5.22 USD |
|
3 years ago
Jan 11, 2022
|
Bought
56.2 K USD
|
Peyer James
director, 10 percent owner:
|
+ 10845
|
5.18 USD |
|
3 years ago
Jan 12, 2022
|
Bought
48 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 9202
|
5.22 USD |
|
3 years ago
Jan 11, 2022
|
Bought
56.2 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 10845
|
5.18 USD |
|
3 years ago
Jan 10, 2022
|
Bought
52.8 K USD
|
Peyer James
director, 10 percent owner:
|
+ 10000
|
5.28 USD |
|
3 years ago
Jan 10, 2022
|
Bought
52.8 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 10000
|
5.28 USD |
|
3 years ago
Dec 30, 2021
|
Bought
5.47 K USD
|
Peyer James
director, 10 percent owner:
|
+ 1127
|
4.85 USD |
|
3 years ago
Dec 30, 2021
|
Bought
5.47 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 1127
|
4.85 USD |
|
3 years ago
Dec 29, 2021
|
Bought
344 K USD
|
Peyer James
director, 10 percent owner:
|
+ 69000
|
4.98 USD |
|
3 years ago
Dec 29, 2021
|
Bought
344 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 69000
|
4.98 USD |
|
3 years ago
Dec 28, 2021
|
Bought
59.6 K USD
|
Peyer James
director, 10 percent owner:
|
+ 11288
|
5.28 USD |
|
3 years ago
Dec 28, 2021
|
Bought
59.6 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 11288
|
5.28 USD |
|
3 years ago
Dec 27, 2021
|
Bought
19.7 K USD
|
Peyer James
director, 10 percent owner:
|
+ 3712
|
5.3 USD |
|
3 years ago
Dec 27, 2021
|
Bought
19.7 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 3712
|
5.3 USD |
|
3 years ago
Dec 23, 2021
|
Bought
58 K USD
|
Peyer James
director, 10 percent owner:
|
+ 11000
|
5.27 USD |
|
3 years ago
Dec 23, 2021
|
Bought
58 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 11000
|
5.27 USD |
|
3 years ago
Dec 17, 2021
|
Bought
619 USD
|
Peyer James
director, 10 percent owner:
|
+ 117
|
5.29 USD |
|
3 years ago
Dec 17, 2021
|
Bought
619 USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 117
|
5.29 USD |
|
3 years ago
Dec 16, 2021
|
Bought
57.4 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 10925
|
5.25 USD |
|
3 years ago
Dec 16, 2021
|
Bought
57.4 K USD
|
Peyer James
director, 10 percent owner:
|
+ 10925
|
5.25 USD |
|
3 years ago
Dec 10, 2021
|
Bought
117 K USD
|
RICKS THOMAS G
Director
|
+ 20000
|
5.86 USD |
|
3 years ago
Dec 09, 2021
|
Bought
132 K USD
|
RICKS THOMAS G
Director
|
+ 20000
|
6.62 USD |
|
3 years ago
Aug 11, 2021
|
Sell 118 K
USD
|
Pierce Robert Hamilton
Chief Scientific Officer
|
- 16030
|
7.3436 USD |
|
3 years ago
Aug 06, 2021
|
Sell 45.9 K
USD
|
Pierce Robert Hamilton
Chief Scientific Officer
|
- 6460
|
7.1127 USD |
|
3 years ago
Aug 09, 2021
|
Sell 49.3 K
USD
|
Pierce Robert Hamilton
Chief Scientific Officer
|
- 6982
|
7.0603 USD |
|
3 years ago
Aug 10, 2021
|
Sell 473 K
USD
|
Pierce Robert Hamilton
Chief Scientific Officer
|
- 66350
|
7.1289 USD |
|
3 years ago
May 05, 2021
|
Bought
4.2 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 350
|
12 USD |
|
3 years ago
May 05, 2021
|
Bought
4.2 K USD
|
Peyer James
director, 10 percent owner:
|
+ 350
|
12 USD |
|
3 years ago
Apr 20, 2021
|
Bought
4.92 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 385
|
12.77 USD |
|
3 years ago
Apr 20, 2021
|
Bought
4.92 K USD
|
Peyer James
director, 10 percent owner:
|
+ 385
|
12.77 USD |
|
3 years ago
Apr 19, 2021
|
Bought
26.3 K USD
|
Peyer James
director, 10 percent owner:
|
+ 1965
|
13.38 USD |
|
3 years ago
Apr 19, 2021
|
Bought
26.3 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 1965
|
13.38 USD |
|
3 years ago
Apr 13, 2021
|
Bought
28 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 2000
|
14 USD |
|
3 years ago
Apr 13, 2021
|
Bought
28 K USD
|
Peyer James
director, 10 percent owner:
|
+ 2000
|
14 USD |
|
3 years ago
Apr 07, 2021
|
Bought
28 K USD
|
Peyer James
director, 10 percent owner:
|
+ 2000
|
14 USD |
|
3 years ago
Apr 07, 2021
|
Bought
28 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 2000
|
14 USD |
|
3 years ago
Apr 01, 2021
|
Bought
14 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 1000
|
14 USD |
|
3 years ago
Apr 01, 2021
|
Bought
14 K USD
|
Peyer James
director, 10 percent owner:
|
+ 1000
|
14 USD |
|
3 years ago
Mar 30, 2021
|
Bought
24 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 2000
|
12 USD |
|
3 years ago
Mar 30, 2021
|
Bought
24 K USD
|
Peyer James
director, 10 percent owner:
|
+ 2000
|
12 USD |
|
3 years ago
Mar 24, 2021
|
Bought
53 K USD
|
Peyer James
director, 10 percent owner:
|
+ 3750
|
14.12 USD |
|
3 years ago
Mar 24, 2021
|
Bought
53 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 3750
|
14.12 USD |
|
3 years ago
Mar 23, 2021
|
Bought
143 K USD
|
Peyer James
director, 10 percent owner:
|
+ 10000
|
14.34 USD |
|
3 years ago
Mar 23, 2021
|
Bought
143 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 10000
|
14.34 USD |
|
3 years ago
Mar 22, 2021
|
Bought
32.8 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 2183
|
15.02 USD |
|
3 years ago
Mar 22, 2021
|
Bought
32.8 K USD
|
Peyer James
director, 10 percent owner:
|
+ 2183
|
15.02 USD |
|
3 years ago
Mar 18, 2021
|
Bought
12.5 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 817
|
15.25 USD |
|
3 years ago
Mar 18, 2021
|
Bought
12.5 K USD
|
Peyer James
director, 10 percent owner:
|
+ 817
|
15.25 USD |
|
3 years ago
Mar 08, 2021
|
Bought
15.2 K USD
|
Peyer James
director, 10 percent owner:
|
+ 1000
|
15.249 USD |
|
3 years ago
Mar 08, 2021
|
Bought
15.2 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 1000
|
15.249 USD |
|
3 years ago
Mar 05, 2021
|
Bought
110 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 8000
|
13.75 USD |
|
3 years ago
Mar 05, 2021
|
Bought
110 K USD
|
Peyer James
director, 10 percent owner:
|
+ 8000
|
13.75 USD |
|
3 years ago
Mar 04, 2021
|
Bought
28.2 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 2000
|
14.125 USD |
|
3 years ago
Mar 03, 2021
|
Bought
47.6 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 3000
|
15.85 USD |
|
3 years ago
Mar 04, 2021
|
Bought
28.2 K USD
|
Peyer James
director, 10 percent owner:
|
+ 2000
|
14.125 USD |
|
3 years ago
Mar 03, 2021
|
Bought
47.6 K USD
|
Peyer James
director, 10 percent owner:
|
+ 3000
|
15.85 USD |
|
3 years ago
Mar 02, 2021
|
Bought
48.8 K USD
|
Peyer James
director, 10 percent owner:
|
+ 3000
|
16.25 USD |
|
3 years ago
Mar 02, 2021
|
Bought
48.8 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 3000
|
16.25 USD |
|
3 years ago
Feb 26, 2021
|
Bought
81.2 K USD
|
Peyer James
director, 10 percent owner:
|
+ 5000
|
16.25 USD |
|
3 years ago
Feb 26, 2021
|
Bought
81.2 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 5000
|
16.25 USD |
|
3 years ago
Feb 25, 2021
|
Bought
189 K USD
|
Peyer James
director, 10 percent owner:
|
+ 12000
|
15.79 USD |
|
3 years ago
Feb 24, 2021
|
Bought
16.6 K USD
|
Peyer James
director, 10 percent owner:
|
+ 900
|
18.42 USD |
|
3 years ago
Feb 24, 2021
|
Bought
305 K USD
|
Peyer James
director, 10 percent owner:
|
+ 18100
|
16.84 USD |
|
3 years ago
Feb 25, 2021
|
Bought
189 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 12000
|
15.79 USD |
|
3 years ago
Feb 24, 2021
|
Bought
16.6 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 900
|
18.42 USD |
|
3 years ago
Feb 24, 2021
|
Bought
305 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 18100
|
16.84 USD |
|
3 years ago
Feb 23, 2021
|
Bought
259 K USD
|
Peyer James
director, 10 percent owner:
|
+ 14300
|
18.1 USD |
|
3 years ago
Feb 23, 2021
|
Bought
102 K USD
|
Peyer James
director, 10 percent owner:
|
+ 6000
|
17.04 USD |
|
3 years ago
Feb 23, 2021
|
Bought
259 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 14300
|
18.1 USD |
|
3 years ago
Feb 23, 2021
|
Bought
102 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 6000
|
17.04 USD |
|
3 years ago
Feb 22, 2021
|
Bought
185 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 9802
|
18.88 USD |
|
3 years ago
Feb 22, 2021
|
Bought
185 K USD
|
Peyer James
director, 10 percent owner:
|
+ 9802
|
18.88 USD |
|
3 years ago
Feb 19, 2021
|
Bought
233 K USD
|
Peyer James
director, 10 percent owner:
|
+ 11786
|
19.77 USD |
|
3 years ago
Feb 19, 2021
|
Bought
233 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 11786
|
19.77 USD |
|
3 years ago
Feb 18, 2021
|
Bought
14.9 K USD
|
Peyer James
director, 10 percent owner:
|
+ 753
|
19.75 USD |
|
3 years ago
Feb 18, 2021
|
Bought
14.9 K USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 753
|
19.75 USD |
|
3 years ago
Feb 08, 2021
|
Bought
0 USD
|
Cambrian BioPharma Inc
10 percent owner
|
+ 110729827
|
0 USD |
7. News
Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi's 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL.
globenewswire.com
- 1 month ago
Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided corporate updates. “The third quarter of 2024 saw significant progress in advancing patient enrollment in the dose expansion portion of the Phase 1 study for SNS-101 across dose levels and patients with primary and acquired resistance to PD-1 inhibitors.
globenewswire.com
- 2 months ago
Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences
BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the Company will present at two upcoming scientific conferences.
globenewswire.com
- 2 months ago
Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that preclinical data on SNS-103 will be presented in a poster session at the CRI-ENCI Eighth International Immunotherapy Conference, being held September 8-11, 2024, at the Gaylord National Resort & Convention Center in National Harbor, MD.
globenewswire.com
- 4 months ago
Sensei Biotherapeutics to Present at Upcoming Conferences
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in September 2024:
globenewswire.com
- 4 months ago
Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided corporate updates. “Collectively, the clinical data presented on SNS-101 over the past six months demonstrated early signs of clinical activity in a patient population generally resistant to immunotherapy, a well-tolerated safety profile, and the avoidance of a pharmacokinetic sink that hindered first-generation approaches to targeting VISTA,” said John Celebi, President and Chief Executive Officer.
globenewswire.com
- 5 months ago
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, being held in New York, NY, on Thursday, June 6, 2024 at 8:30 a.m. ET.
globenewswire.com
- 7 months ago
Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?
Sensei Biotherapeutics (NASDAQ: SNSE ) stock is falling on Friday after it failed to impress investors with its latest Phase 1/2 clinical trial data for SNS-101. SNS-101 is a human monoclonal antibody targeting the immune checkpoint VISTA.
investorplace.com
- 7 months ago
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101
- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00 a.m. ET - BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported encouraging clinical data from the dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).
globenewswire.com
- 7 months ago
EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member
PARIS--(BUSINESS WIRE)--EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Pejvack Motlagh MD, MSc, as Chief Medical Officer and John Celebi, as Independent Board Member. “We are excited to welcome Pejvack and John at Egle and to benefit from their strong experience. The appointment of Dr Motlagh is critical for Egle, as the company.
businesswire.com
- 8 months ago
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion portion of the clinical study advancing - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provided corporate updates. “Building upon our initial data for SNS-101, which we believe support a favorable and potentially best-in-class clinical safety and PK profile, we now look forward to sharing topline dose escalation data at ASCO in June and initial dose expansion data in the fourth quarter of this year,” said John Celebi, President and Chief Executive Officer.
globenewswire.com
- 8 months ago
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), will be presented in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024.
globenewswire.com
- 8 months ago
8. Profile
Summary
Sensei Biotherapeutics, Inc. SNSE
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 13.3 M
Dividend Yield
0.00%
Description
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Contact
451 D Street, Rockville, MD, 02210
https://www.senseibio.com
IPO
Date
Feb. 4, 2021
Employees
28
Officers
Dr. Edward Van der Horst Ph.D.
Chief Scientific Officer
Mr. John K. Celebi M.B.A.
President, Chief Executive Officer & Director
Ms. Lora Pike
Vice President of Investor Relations & Communications
Mr. Josiah Craver
Senior Vice President of Finance, Principal Financial Officer & Principal Accounting Officer
Mr. Christopher W. Gerry J.D.
Senior Vice President, General Counsel & Secretary
Ms. Stephanie Krebs M.B.A., M.S.
Chief Business Officer
Dr. Aaron Weitzman FACP, M.D., Ph.D.
Chief Medical Officer